Home > Market > Market Stats >  Sanofi India

Sanofi India

Sector: Biotechnology & Drugs
Powered by
5822.05 +27.35 (0.47%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 5751.05
Today’s High 5822.2
52 Week Low 5751.05
52 Week High 7860.67

Key Metrics

  • Market Cap (In Cr) 13336
  • Beta 0.54
  • Div. Yield (%) 3.13
  • P/B 5.99
  • TTM P/E 14.7
  • Peg Ratio -0.37
  • Sector P/E 24.66
  • D/E 0.02
  • Open Price 5751.05
  • Prev Close 5794.7
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -2.68%
  • 3 Months
    -7.34%
  • 6 Month
    -17.21%
  • YTD
    -21.28%
  • 1 Year
    -20.25%
Risk Meter
  • 18% Low risk
  • 18% Moderate risk
  • 18% Balanced Risk
  • 18% High risk
  • 18% Extreme risk
Recos
8 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 1
  • Sell
  • 0
  • Hold
  • 1
  • Buy
  • 2
  • Strong Buy
  • 4

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2021
  • Total Revenue
  • 2956.6
  • Selling/ General/ Admin Expenses Total
  • 876.7
  • Depreciation/ Amortization
  • 66.7
  • Other Operating Expenses Total
  • -0.1
  • Total Operating Expense
  • 1771.5
  • Operating Income
  • 1185.1
  • Net Income Before Taxes
  • 1257.6
  • Net Income
  • 944.4
  • Diluted Normalized EPS
  • 248.4
  • Period
  • 2020
  • Total Revenue
  • 2901.9
  • Selling/ General/ Admin Expenses Total
  • 918
  • Depreciation/ Amortization
  • 82.2
  • Other Operating Expenses Total
  • -0.1
  • Total Operating Expense
  • 2309.8
  • Operating Income
  • 592.1
  • Net Income Before Taxes
  • 677.2
  • Net Income
  • 477.6
  • Diluted Normalized EPS
  • 221
  • Period
  • 2019
  • Total Revenue
  • 3070.6
  • Selling/ General/ Admin Expenses Total
  • 1034.3
  • Depreciation/ Amortization
  • 99.9
  • Other Operating Expenses Total
  • -0.3
  • Total Operating Expense
  • 2562.3
  • Operating Income
  • 508.3
  • Net Income Before Taxes
  • 599.9
  • Net Income
  • 414.2
  • Diluted Normalized EPS
  • 198.2
  • Period
  • 2018
  • Total Revenue
  • 2770.8
  • Selling/ General/ Admin Expenses Total
  • 954.9
  • Depreciation/ Amortization
  • 102.7
  • Other Operating Expenses Total
  • 22.8
  • Total Operating Expense
  • 2248.1
  • Operating Income
  • 522.7
  • Net Income Before Taxes
  • 609.8
  • Net Income
  • 380.6
  • Diluted Normalized EPS
  • 165.75
  • Period
  • 2017
  • Total Revenue
  • 2491.4
  • Selling/ General/ Admin Expenses Total
  • 895.9
  • Depreciation/ Amortization
  • 102.2
  • Other Operating Expenses Total
  • 31.9
  • Total Operating Expense
  • 2055
  • Operating Income
  • 436.4
  • Net Income Before Taxes
  • 514.6
  • Net Income
  • 326
  • Diluted Normalized EPS
  • 141.91
  • Period
  • 2016
  • Total Revenue
  • 2419.7
  • Selling/ General/ Admin Expenses Total
  • 769
  • Depreciation/ Amortization
  • 118.8
  • Other Operating Expenses Total
  • 32.3
  • Total Operating Expense
  • 2003.2
  • Operating Income
  • 416.5
  • Net Income Before Taxes
  • 480.4
  • Net Income
  • 304.2
  • Diluted Normalized EPS
  • 132.03
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day5859.82
  • 10 Day5930.96
  • 20 Day6018.01
  • 50 Day6217.58
  • 100 Day6301.99
  • 300 Day6632.49

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 26-Jul-22
  • Quarterly Results & Interim Dividend
  • 26-Apr-22
  • Quarterly Results
  • 23-Feb-22
  • Audited Results & Final Dividend
  • 26-Oct-21
  • Quarterly Results
  • 27-Jul-21
  • Quarterly Results
  • 27-Apr-21
  • Quarterly Results
  • 23-Feb-21
  • Audited Results & Final Dividend

Company Profile

ABOUT Sanofi India

  • Industry Biotechnology & Drugs
  • ISIN INE058A01010
  • BSE Code 500674
  • NSE Code SANOFI

Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals products. The Company’s products are offered across four categories, which includes pharmaceuticals, consumer health care, vaccines and specialty care. It offers medicines for therapy areas, such as diabetes (both insulins and orals), cardiology, thrombosis, anti-infectives, central nervous system, allergy and vitamins, and minerals and supplements. Its pharmaceutical products include Adenocor, Lantus, Aldurazyme, AllStar, Amaryl MP, Amaryl M, Apidra, Arava, Aubagio and Thymoglobuline. Its specialty care products include Myozyme, Cerezyme, Aldurazyme, Aubagio and Jevtana. Its consumer healthcare products include Allegra, Allegra nasal, Avil, Combiflam, Combiflam Plus and Lactacyd. Its vaccines products include Adacel, Avaxim 80U/160U, FluQuadri, Hexaxim, Menactra, Tetraxim, Vaxigrip, Stamaril, Shanvac-B and ShanTT.

MANAGEMENT

  • Vaibhav Karandikar Chief Financial Officer, Whole-Time Director
  • Radhika Shah Compliance Officer, Company Secretary
  • Rodolfo Hrosz Managing Director, Whole Time Director
  • Cherian Mathew Whole Time Director
  • Bratin Bag Senior Director - EBI, South Asia
  • Gaurav Bahadur Senior Director - Human Resources, India and South Asia
  • Shalini Menon Medical Head, India, India Medical Lead
  • Vinita Patil Senior Legal Director - South Asia
  • Yasmin Shenoy Senior Director - Regulatory Affairs
  • Aparna Thomas Senior Director - Corporate Communications and Corporate Social Responsibility, India and South Asia

Company Summary

SANOFI INDIA SUMMARY

Sanofi India is trading 0.47% upper at Rs 5822.05 as compared to its last closing price. Sanofi India has been trading in the price range of 5822.2 & 5751.05. Sanofi India has given -21.28% in this year & -2.68% in the last 5 days.

 

Sanofi India has TTM P/E ratio 14.7 as compared to the sector P/E of 24.66. There are 8 analysts who have initiated coverage on Sanofi India. There are 4 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

 

The company posted a net profit of 120.4 Crores in its last quarter.

 

Listed peers of Sanofi India include Ajanta Pharma (-0.88%), J B Chemicals & Pharmaceuticals (0.04%), Sanofi India (0.47%) etc.

FAQs about Sanofi India

Sanofi India is trading at 5822.05 as on 30 Sep, 2022 3:29:52 PM. This is 0.47% upper as compared to its previous closing price of 5794.7
The market capitalization of Sanofi India is 13336 Cr as on 30 Sep, 2022 3:29:52 PM.
The average broker rating on Sanofi India is Buy. The breakup of analyst rating is given below -
  • 1 analysts have given a strong sell rating
  • 0 analysts have given a sell rating
  • 1 analysts have given a hold rating
  • 2 analysts have given a buy rating
  • 4 analysts have given a strong buy rating
The 52 wk high for Sanofi India is 7860.67 whereas the 52 wk low is 5751.05
Sanofi India can be analyzed on the following key metrics -
  • TTM P/E: 14.7
  • Sector P/E: 24.66
  • Dividend Yield: 3.13%
  • D/E ratio: -
Sanofi India reported a net profit of 944.4 Cr in 2021.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout